Last edition
News about Global Pharma
AstraZeneca has announced a historic agreement with President Donald Trump’s administration to lower the cost of prescription medicines for American patients while strengthening the nation’s biopharmaceutical innovation base.
Global Pharma | 11/10/2025 | By Dineshwori | 190
Shuttle Pharmaceuticals Signs LOI to Acquire Molecule.ai in USD 10 Million Deal
US-based specialty pharmaceutical company Shuttle Pharmaceuticals Holdings has signed a non-binding Letter of Intent (LOI) to acquire Molecule.ai, an advanced artificial intelligence firm revolutionising drug discovery and development.
Global Pharma | 10/10/2025 | By Dineshwori | 320
Lonza has received Swissmedic approval for its new state-of-the-art aseptic filling line in Stein (CH), designed for biologics and highly potent products, including antibody-drug conjugates (ADCs).
Global Pharma | 10/10/2025 | By Dineshwori | 230
Novo Nordisk to Acquire Akero Therapeutics Alongside Promising MASH Therapy Efruxifermin
Danish pharma giant Novo Nordisk has signed a definitive agreement to acquire Akero Therapeutics, a San Francisco-based clinical-stage biopharmaceutical company focused on developing innovative therapies for serious metabolic diseases.
Global Pharma | 10/10/2025 | By Dineshwori | 341
Jubilant HollisterStier LLC (JHS) — a wholly owned subsidiary of Jubilant Pharmova and a leading North American contract manufacturer specialising in sterile injectables — has launched a new Sterile Fill & Finish line, its third at the Spokane manufacturing facility in Washington, USA.
Global Pharma | 10/10/2025 | By Dineshwori | 273
Thermo Fisher Launches Molecular Microscope to Assess Lung Transplant Rejection
Thermo Fisher’s new Molecular Microscope Diagnostic System for Lung (MMDx Lung) leverages the power of Machine Learning (ML) to profile gene expression data from lung biopsies, comparing each new sample to a reference set of over 896 lung biopsies.
Global Pharma | 10/10/2025 | By Dineshwori | 150
Jascayd is the first and only preferential inhibitor of phosphodiesterase 4B (PDE4B) to be approved in this indication. This represents a novel mechanism of action that exerts both antifibrotic and immunomodulatory effects, thereby slowing the decline in lung function in IPF patients.
Global Pharma | 10/10/2025 | By Dineshwori | 474
XenoTherapeutics Completes Takeover of Canada's ESSA Pharma
Canada-based ESSA Pharma has announced the completion of its acquisition by XenoTherapeutics, a US-based research foundation focused on advancing xenotransplantation therapies.
Global Pharma | 10/10/2025 | By Dineshwori | 397
By deploying the ExellenS framework across its manufacturing network—with standardised designs, unified processes, and advanced digital integration—Samsung Biologics ensures plant equivalency, operational speed, and seamless manufacturing continuity.
Global Pharma | 10/10/2025 | By Dineshwori | 273
CTx001, an AAV-based gene therapy, delivers a mini-CR1 protein to modulate complement pathways and address Geographic Atrophy (GA), an advanced dry AMD causing irreversible vision loss.
Global Pharma | 09/10/2025 | By Dineshwori | 178
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy